<?xml version='1.0' encoding='utf-8'?>
<document id="29626326"><sentence text="Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics." /><sentence text="The objective of this study was to develop a physiologically based pharmacokinetic (PBPK) model for sinogliatin (HMS-5552, dorzagliatin) by integrating allometric scaling (AS), in vitro to in vivo exploration (IVIVE), and steady-state concentration-mean residence time (Css-MRT) methods and to provide mechanistic insight into its pharmacokinetic properties in humans"><entity charOffset="100-111" id="DDI-PubMed.29626326.s2.e0" text="sinogliatin" /><entity charOffset="113-121" id="DDI-PubMed.29626326.s2.e1" text="HMS-5552" /><pair ddi="false" e1="DDI-PubMed.29626326.s2.e0" e2="DDI-PubMed.29626326.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29626326.s2.e0" e2="DDI-PubMed.29626326.s2.e1" /></sentence><sentence text="" /><sentence text="Human major pharmacokinetic parameters were analyzed using AS, IVIVE, and Css-MRT methods with available preclinical in vitro and in vivo data to understand sinogliatin drug metabolism and pharmacokinetic (DMPK) characteristics and underlying mechanisms" /><sentence text=" On this basis, an initial mechanistic PBPK model of sinogliatin was developed"><entity charOffset="53-64" id="DDI-PubMed.29626326.s5.e0" text="sinogliatin" /></sentence><sentence text=" The initial PBPK model was verified using observed data from a single ascending dose (SAD) study and further optimized with various strategies" /><sentence text=" The final model was validated by simulating sinogliatin pharmacokinetics under a fed condition"><entity charOffset="45-56" id="DDI-PubMed.29626326.s7.e0" text="sinogliatin" /></sentence><sentence text=" The validated model was applied to support a clinical drug-drug interaction (DDI) study design and to evaluate the effects of intrinsic (hepatic cirrhosis, genetic) factors on drug exposure" /><sentence text="" /><sentence text="The two-species scaling method using rat and dog data (TS-rat,dog) was the best AS method in predicting human systemic clearance in the central compartment (CL)" /><sentence text=" The IVIVE method confirmed that sinogliatin was predominantly metabolized by cytochrome P450 (CYP) 3A4"><entity charOffset="33-44" id="DDI-PubMed.29626326.s11.e0" text="sinogliatin" /></sentence><sentence text=" The Css-MRT method suggested dog pharmacokinetic profiles were more similar to human pharmacokinetic profiles" /><sentence text=" The estimated CL using the AS and IVIVE approaches was within 1" /><sentence text="5-fold of that observed" /><sentence text=" The Css-MRT method in dogs also provided acceptable prediction of human pharmacokinetic characteristics" /><sentence text=" For the PBPK approach, the 90% confidence intervals (CIs) of the simulated maximum concentration (Cmax), CL, and area under the plasma concentration-time curve (AUC) of sinogliatin were within those observed and the 90% CI of simulated time to Cmax (tmax) was closed to that observed for a dose range of 5-50 mg in the SAD study" /><sentence text=" The final PBPK model was validated by simulating sinogliatin pharmacokinetics with food"><entity charOffset="50-61" id="DDI-PubMed.29626326.s17.e0" text="sinogliatin" /></sentence><sentence text=" The 90% CIs of the simulated Cmax, CL, and AUC values for sinogliatin were within those observed and the 90% CI of the simulated tmax was partially within that observed for the dose range of 25-200 mg in the multiple ascending dose (MAD) study" /><sentence text=" This PBPK model selected a final clinical DDI study design with itraconazole from four potential designs and also evaluated the effects of intrinsic (hepatic cirrhosis, genetic) factors on drug exposure"><entity charOffset="65-77" id="DDI-PubMed.29626326.s19.e0" text="itraconazole" /></sentence><sentence text="" /><sentence text="Sinogliatin pharmacokinetic properties were mechanistically understood by integrating all four methods and a mechanistic PBPK model was successfully developed and validated using clinical data"><entity charOffset="0-11" id="DDI-PubMed.29626326.s21.e0" text="Sinogliatin" /></sentence><sentence text=" This PBPK model was applied to support the development of sinogliatin"><entity charOffset="59-70" id="DDI-PubMed.29626326.s22.e0" text="sinogliatin" /></sentence><sentence text="" /></document>